Stock Ratings / Health Care / BEAT / earnings

DRIO (36) NEPH (73) CVRX (43) XTNT (69) ⌘ Pro Terminal →

Heartbeam Inc. (BEAT) Next Earnings Date & Expected ±12.5% Move

$0.54 +1.34% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.54

Heartbeam Inc. (BEAT) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY) →

ROARABLE D • SELL / AVOID Cap $30.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BEAT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BEAT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-01, Heartbeam Inc. (NASDAQ: BEAT) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $0.54 (+1.34% 1D, market cap $30.4M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BEAT ranks #352 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BEAT compare to DRIO and NEPH in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), BEAT carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DRIO (DarioHealth Corp.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $32.4M) and NEPH (Nephros Inc.) posts a B grade (73/100 RQD, P/E 29.8x, ROIC 18.9%, cap $35.5M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BEAT?

▼

Per BEAT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001779372), Heartbeam Inc. generated $0 in revenue, -$21.0M in net income, and -$14.6M in free cash flow against $5.8M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.54 (+0.05%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-3.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BEAT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (50/100 Composite)

🔍 WHY BEAT SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (30% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (26% of score)

FRED Regime × Technicals: 5% of 52W Range • RSI-14 at 63.4 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.48-8.3% Next Q

Q2 (-2Q)

Grade D$0.44-11.4% Next Q

Q3 (-1Q)

Grade D$0.39+38.5% Next Q

Current

Grade D$0.54-1.4% Hist 90D α

Trajectory: D (42) → D (50)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BEAT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BEAT currently carries a cautious 50/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.44) and Max Pain ($0.57) forces dealer call-delta covering toward $4.20.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BEAT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BEAT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 50%NO 50%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.07 Expected Swing

MODEL EARNINGS SETUP GAUGE

BEAT Quantitative Pre-Earnings Setup: 50/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (50/100)Model Risk Weight (50/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	-$21.0M	-$14.6M	52%
FY 2024	2024-12-31	$0	-$19.4M	-$14.7M	52%
FY 2023	2023-12-31	$0	-$14.6M	-$12.1M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BEAT)

✓Walkthrough of BEAT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BEAT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -37.21%📐 HORIZONTAL RANGE

2026-10-30O $0.54H $0.56L $0.52C $0.54VOL 1.57M

RES: $0.95SUP: $0.27SMA50: $0.44SMA200: $0.86

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BEAT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BEAT Butterfly Map → + Track BEAT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BEAT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BEAT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BEAT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BEAT)

Health Care Rank #352 of 1016 ⚔️ DRIO vs BEAT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BEAT vs. DRIO, NEPH, CVRX, XTNT)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Heartbeam Inc. (BEAT) ranks #352 by composite RQD confidence (50/100, grade D) and #803 by equity capitalization ($30.4M). Within this direct 5-issuer industry benchmark cohort, NEPH leads on earnings valuation at 29.8x trailing P/E, while NEPH leads on capital efficiency and profitability with 18.9% ROIC and 61.9% gross margin. NEPH currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with BEAT at 50/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BEAT ACTIVE Heartbeam Inc.	D	50/100	—	—	-35.0%	+1.34%	$30.4M	Benchmark Subject
DRIO DarioHealth Corp.	D-	36/100	—	56.6%	-35.0%	-2.93%	$32.4M	/drio-vs-beat →
NEPH Nephros Inc.	B	73/100	29.8x	61.9%	18.9%	+3.16%	$35.5M	/neph-vs-beat →
CVRX CVRx Inc.	D-	43/100	—	85.3%	-35.0%	+1.79%	$38.0M	/cvrx-vs-beat →
XTNT Xtant Medical Holdings Inc.	C+	69/100	—	62.9%	12.8%	+1.54%	$40.7M	/xtnt-vs-beat →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001779372

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Heartbeam Inc. (BEAT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$21.0M, operating cash flow of -$14.0M, and free cash flow of -$14.6M (+0.6% YoY). On the balance sheet, BEAT closed FY2025 with $5.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$21.0M	-$14.0M	-$14.6M	$5.8M	—
FY2024 (FY)	2024-12-31	$0	-$19.4M	-$14.5M	-$14.7M	$3.3M	—
FY2023 (FY)	2023-12-31	$0	-$14.6M	-$12.1M	-$12.1M	—	—

3. BEAT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BEAT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BEAT compare to DRIO and NEPH in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BEAT?

Where is BEAT trading relative to its 50-day, 200-day, and 52-week technical levels?

BEAT last traded at $0.54 (+1.34% on volume of 2,476,521 shares), positioning the stock +22.73% above its 50-day simple moving average ($0.44) and -37.21% below its 200-day simple moving average ($0.86). Across its 52-week range of $0.36 to $4.00, BEAT sits at the 4.9% percentile with a 14-day RSI of 63.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.00 to $0.61).

BEAT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is BEAT's next earnings date?

Based on SEC filing cadence, Heartbeam Inc. (BEAT)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is BEAT stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for BEAT, spanning a range between $1 and $0.61.

Direct Sub-Reports: BEAT RQD Cockpit BEAT 12M Forecast BEAT Earnings & Move BEAT Dividends & DRIP BEAT Insiders & 13F BEAT Whale Options BEAT Profit Sankey BEAT News & Why